Eli Lilly and Co
Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers
Most analysts predict the market for new weight loss drugs like Wegovy and Mounjaro will be enormous, but estimates vary for its exact size depending on who you ask. On Monday, Citi raised its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That viewpoint seems […]
Read More
These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass
One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. What this means for patients over the long term isn’t fully known, but there are several pharmaceutical companies studying the side effect and hoping to develop therapies that might regulate the condition. In […]
Read More
Sanofi to offer insulin product for $35 to all Americans through GoodRx
Sanofi Lantus brand insulin pens are arranged for a photograph in the Brooklyn borough of New York, U.S., on Friday, April 5, 2019. Alex Flynn | Bloomberg | Getty Images Americans, regardless of their insurance status, can now access Sanofi‘s most widely prescribed insulin for $35 through the prescription drug savings company GoodRx, the companies […]
Read More
CNBC Professional Talks: Munro Partners’ Nick Griffin to examine AI, Significant Tech and stocks to short
Artificial intelligence shares have been on a tear this 12 months, but is it too late to spend? Sign up for CNBC’s Will Koulouris as he quizzes Nick Griffin, chief investment decision officer of Munro Associates, on the AI concept, Big Tech, and how to enjoy shares this sort of as Nvidia and Microsoft . Submit […]
Read More
When is it OK to violate your cost basis to buy more shares of a company?
Here’s our Club Mailbag email [email protected] — so you send your questions directly to Jim Cramer and his team of analysts. We can’t offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries. This week’s question: The cardinal rule of discipline is […]
Read More
‘Miracle drug’ euphoria: Specialists warn widespread use of fat decline medicine faces main hurdles
Two gurus see key difficulties facing the adoption of new being overweight medicine. Dr. Kavita Patel, a physician and NBC News health-related contributor, thinks new knowledge from Novo Nordisk on Ozempic’s means to hold off the development of long-term kidney disease is among the strongest supporting proof for secondary uses of the drug. On the […]
Read More
Many are betting Ozempic will reduce the need for knee surgery. What it means if they’re wrong
Medical device stocks of all kinds were pummeled over the past week as investors tried to calculate the ripple effects of new weight loss drugs. It wasn’t the first rout in the sector — the pressure has persisted for several months. The fear has been that whenever you have a large group of consumers changing […]
Read More
Monthly Meeting Q&A with Jim Cramer on everything from tech to health care to industrials
During the October Monthly Meeting , we took questions directly from Investing Club members. Here are Jim Cramer’s and portfolio director Jeff Marks’ responses. Their answers have been edited for clarity. 1. Why do rising interest rates have such a negative effect on technology stocks? (Rod) Jim Cramer: When the Federal Reserve started raising rates, […]
Read More
Here’s a rapid-fire update on all 36 stocks in our portfolio, including our latest addition
Jim Cramer ran through the names during the Club’s October Monthly Meeting on Wednesday. Source
Read More
15 stocks with a history of dividend growth are expected to deliver once again this year
Broadcom (AVGO), Caterpillar (CAT) and Eli Lilly (LLY) are among the 15 Club stocks with a streak of annual dividend growth that Wall Street expects to continue in their current fiscal years. Long-term investors should look to own companies with a history of dividend growth instead of chasing stocks with high yields, Morgan Stanley strategists […]
Read More